Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 19/20 | 0.69 |
| ▸ | PKM | P14618 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16943474 | 0.88 | MAPT (0.65) | MAPTPKMALDH1A1SMN1; SMN2NPSR1 | |
| SCHEMBL18036523 | 0.86 | MAPT (0.75) | MAPTPKMALDH1A1SMN1; SMN2NPSR1 | |
| SCHEMBL40059 | 0.84 | HPGD (0.68) | MAPTPKMALDH1A1SMN1; SMN2NPSR1 | |
| SCHEMBL2589998 | 0.82 | MAPT (0.69) | MAPTPKMALDH1A1SMN1; SMN2NPSR1 | |
| SCHEMBL2445796 | 0.82 | LMNA (0.75) | MAPTPKMALDH1A1SMN1; SMN2NPSR1 | |
| SCHEMBL443596 | 0.82 | HPGD (0.73) | MAPTPKMALDH1A1SMN1; SMN2NPSR1 | |
| SCHEMBL1911905 | 0.82 | MAPT (1.00) | MAPTPKMALDH1A1SMN1; SMN2NPSR1 | |
| SCHEMBL5058321 | 0.82 | MAPT (0.69) | MAPTPKMALDH1A1SMN1; SMN2NPSR1 | |
| SCHEMBL2910036 | 0.82 | SIRT6 (0.69) | MAPTALDH1A1MAPK1 | |
| SCHEMBL29788558 | 0.82 | HPGD (0.73) | MAPTPKMALDH1A1SMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4618977-A1 | LRRK2 INHIBITORS AND USES THEREOF | Neuron23, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| CN-119775277-A | Compounds as modulators of LRRK2, NUAK1 and/or TYK2 kinases for the treatment of, for example, autoimmune diseases | 原真股份有限公司 | 2025-04-08 | — | — | CN | disclosed |
| CN-114793435-B | Compounds as modulators of LRRK2, NUAK1 and/or TYK2 kinases for the treatment of, for example, autoimmune diseases | 原真股份有限公司 | 2024-10-01 | — | — | CN | disclosed |
| US-20240228493-A1 | LRRK2 INHIBITORS AND USES THEREOF | NEURON23, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228493-A1 | LRRK2 INHIBITORS AND USES THEREOF | NEURON23, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228493-A1 | LRRK2 INHIBITORS AND USES THEREOF | NEURON23, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240208972-A1 | LRRK2 INHIBITORS AND USES THEREOF | NEURON23, INC. | 2024-06-27 | — | — | US | disclosed |
| WO-2024108128-A1 | LRRK2 INHIBITORS AND USES THEREOF | NEURON23, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| WO-2024108116-A1 | LRRK2 INHIBITORS AND USES THEREOF | NEURON23, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| EP-4327884-A2 | 1,4-DIHYDROBENZO[D]PYRAZOLO[3,4-F][1,3]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS LRRK2, NUAK1 AND/OR TYK2 KINASE MODULATORS FOR THE TREATMENT OF E.G. AUTOIMMUNE DISEASES | Origenis GmbH (DE) | 2024-02-28 | — | — | EP | disclosed |
| CN-115103844-A | 1, 4-dihydrobenzo [ D ] pyrazolo [3,4-F ] [1,3] diazepine derivatives and related compounds as modulators of LRRK2, NUAK1 and/or TYK2 kinases for the treatment of e.g. autoimmune diseases | 原真股份有限公司 | 2022-09-23 | — | — | CN | disclosed |
| CN-111217816-B | FLT3 kinase inhibitor and preparation and application thereof | 中国科学院上海药物研究所 | 2022-08-16 | — | — | CN | disclosed |
| CN-114793435-A | 1, 4-dihydrobenzo [ D ] pyrazolo [3,4-F ] [1,3] diazepine derivatives and related compounds as modulators of LRRK2, NUAK1, and/or TYK2 kinases for the treatment of, for example, autoimmune diseases | 原真股份有限公司 | 2022-07-26 | — | — | CN | disclosed |
| EP-4028017-A1 | 1,4-DIHYDROBENZO[D]PYRAZOLO[3,4-F][1,3]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS LRRK2, NUAK1 AND/OR TYK2 KINASE MODULATORS FOR THE TREATMENT OF E.G. AUTOIMMUNE DISEASE | Origenis GmbH (DE) | 2022-07-20 | — | — | EP | disclosed |
| EP-4028016-A1 | 1,4-DIHYDROBENZO[D]PYRAZOLO[3,4-F][1,3]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS LRRK2, NUAK1 AND/OR TYK2 KINASE MODULATORS FOR THE TREATMENT OF E.G. AUTOIMMUNE DISEASE | Origenis GmbH (DE) | 2022-07-20 | — | — | EP | disclosed |
| US-20210128556-A1 | AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2021-05-06 | — | — | US | disclosed |
| WO-2021048618-A1 | 1,4-DIHYDROBENZO[D]PYRAZOLO[3,4-F][1,3]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS LRRK2, NUAK1 AND/OR TYK2 KINASE MODULATORS FOR THE TREATMENT OF E.G. AUTOIMMUNE DISEASE | ORIGENIS GMBH (DE) | 2021-03-18 | — | — | WO | disclosed |
| WO-2021048620-A1 | 1,4-DIHYDROBENZO[D]PYRAZOLO[3,4-F][1,3]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS LRRK2, NUAK1 AND/OR TYK2 KINASE MODULATORS FOR THE TREATMENT OF E.G. AUTOIMMUNE DISEASE | ORIGENIS GMBH (DE) | 2021-03-18 | — | — | WO | disclosed |
| US-20200354352-A1 | PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2020-11-12 | — | — | US | disclosed |
| CN-111217816-A | FLT3 kinase inhibitor and preparation and application thereof | 中国科学院上海药物研究所 | 2020-06-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210128556-A1 | AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | BECN1, SQSTM1, ATG7 | MAPT 940/4885PKM 1845/4885ALDH1A1 2251/4885 |
| US-20200354352-A1 | PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | BECN1, SQSTM1, ATG7 | MAPT 817/4885PKM 1207/4885ALDH1A1 2271/4885 |
| US-20240208972-A1 | LRRK2 INHIBITORS AND USES THEREOF | LRRK2, PINK1, PARK7 | MAPT 151/4885PKM 690/4885ALDH1A1 4316/4885 |
| US-20240228493-A1 | LRRK2 INHIBITORS AND USES THEREOF | LRRK2, PINK1, PARK7 | MAPT 151/4885PKM 690/4885ALDH1A1 4316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.